U.S. Agencies Seize Over $7 Million in Illegal E-Cigarettes as FDA Pledges Continued Crackdown

Jan.11.2025
U.S. Agencies Seize Over $7 Million in Illegal E-Cigarettes as FDA Pledges Continued Crackdown
The Miami operation, announced on January 10, is the latest joint effort by multiple U.S. federal agencies to combat illegal e-cigarettes, resulting in the seizure of over $7 million worth of unauthorized products. The FDA emphasized that an “All Government” approach is critical in addressing the issue of illegal e-cigarettes.

Key Points:

 

1. This is another significant enforcement action following the October 2024 seizure of $76 million worth of illegal e-cigarettes.

 

2. Recently, the FDA has issued a series of announcements, including the January 3 announcement regarding updates to import alerts, allowing all unauthorized e-cigarettes to be detained without physical examination. These actions signal an acceleration of the FDA’s crackdown on illegal e-cigarettes.

 

3. In this announcement, Geek Bar was once again the only brand explicitly named, with the FDA stating that it “may appeal to youth.” This underscores the FDA’s close attention to the brand.

 

4. The details disclosed in this announcement—such as the seizure in Miami and the methods by which illegal products entered the U.S.—demonstrate the increasing precision and efficiency of enforcement under multi-agency cooperation.

 

5. The head of the FDA’s Center for Tobacco Products emphasized the importance of the “All Government” approach, in combating illegal e-cigarettes. This suggests that additional cases of illegal e-cigarette seizures may occur in the future.

 

 

 

[January 10, 2025] U.S. federal agencies announced the seizure of more than 628,000 unauthorized e-cigarette products from a warehouse in Miami, with a retail value exceeding $7 million. The confiscated items included flavored disposable e-cigarettes, kits, and batteries, with some products from brands like Geek Bar, which are known to appeal to youth.

 

The operation, led by U.S. Customs and Border Protection (CBP), uncovered shipments of illegal e-cigarette products originating from China and destined for various U.S. states. Investigations revealed that these products were intentionally misdeclared and undervalued—common tactics to evade detection and duties. Following referrals to the FDA’s Center for Tobacco Products, authorities confirmed the products lacked mandatory premarket authorization, rendering them illegal for sale or distribution in the U.S.

 

“An ‘All Government’ approach is critical to preventing unauthorized e-cigarettes from entering the United States” said Brian King, Ph.D., M.P.H., director of the FDA’s Center for Tobacco Products. “Today’s action is another step in the right direction, and we remain committed to continuing to work with our federal partners to continue to combat the entry of these illegal products head on.”

 

Confiscated products, like those seized in this operation, are typically disposed of in compliance with federal regulations. For unauthorized tobacco products, including e-cigarettes, this generally means destruction.

 

The Miami operation is part of an intensified federal crackdown on illegal e-cigarette distribution. It follows a $76 million seizure of unauthorized e-cigarettes in October 2024 and builds on efforts spearheaded by a federal task force established in June 2024 to streamline enforcement. These coordinated actions aim to hold violators accountable by leveraging criminal and civil tools across multiple agencies.

 

To date, the FDA has authorized only 34 e-cigarette products and devices for legal sale in the U.S. More information on authorized tobacco products can be found in the FDA’s Searchable Tobacco Products Database.

 

Original FDA Announcement : Over $7 Million Worth of Illegal E-Cigarettes Seized in Federal Operation

 

 

 

2Firsts Editorial Note:

 

Since the second half of 2024, U.S. agencies have continued their crackdown on illegal e-cigarettes. Through coordinated efforts across multiple federal departments, these enforcement actions have achieved increasingly significant results, reflecting the U.S. federal government’s determination and strategic optimization in combating illegal e-cigarettes.

 

2Firsts has been closely monitoring U.S. regulatory actions on e-cigarettes. At the recently concluded 2Firsts 2024 Global NGP Compliance Development Symposium, 2Firsts invited several U.S. compliance experts to provide detailed insights into U.S. compliance policies for e-cigarette companies. Additionally, in 2Firsts’ 2024 Global Top 10 NGP News, the story titled “1. U.S. E-Cigarette Regulations Intensify, Setting the Stage for a Major Market Shakeup” ranked first.

 

 

 

Recent 2Firsts reports on U.S. regulations include:

 

1.FDA Strengthens Import Alerts to Address Unauthorized E-Cigarettes Detention

 

2.FDA Warns 9 Online Firms for Illegally Selling Flavored, Disposable E-Cigarettes, Including Geek Bar and Lost Mary

 

3.FDA Outlines Recent Regulatory Actions to 2Firsts: Comprehensive Oversight and Strategies Adapting to Market Changes


4.U.S. FDA's 2024 Illicit E-Cigarette Crackdown: Full-Spectrum Enforcement and Targeted Actions Against Geekvape and Heaven Gifts

 

5.FDA, CBP seize 3 million illegal e-cigarette products worth $76 million, including GEEKBAR

 

6.U.S. Regulatory Storm to Drive Profound Changes in China's E-Cigarette Supply Chain, Says Alan Zhao, CEO of 2Firsts

 


 

2Firsts welcomes article submissions, interview opportunities, or commentary. Please contact us at info@2firsts.com or connect with 2Firsts CEO Alan Zhao on LinkedIn here.

 

FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Several U.S. states have incorporated the September 9, 2020 PMTA filing deadline into eligibility rules for certain vaping products. CrossBar 20K drew attention after appearing on Pennsylvania's 163-entry directory. A broader 2Firsts investigation found that related registration businesses also listed KUMI and CROSSBAR SIX products, with 171 KUMI-related entries across Louisiana, Nebraska and Wisconsin. Corporate records link Scott Silverman to Blue Nine LLC and VR Products I LLC. PMTA compliance expert Mr. K said historical applications and nicotine-analogue products may offer two different approaches to state-directory access.
Regulations
Oct.26
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22